Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) EBITDA Margin (2024 - 2025)

Prime Medicine (PRME) has disclosed EBITDA Margin for 2 consecutive years, with 5492.84% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 355532.0% year-over-year to 5492.84%, compared with a TTM value of 4340.7% through Dec 2025, up 222538.0%, and an annual FY2025 reading of 4340.7%, up 222538.0% over the prior year.
  • EBITDA Margin was 5492.84% for Q4 2025 at Prime Medicine, down from 4125.63% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1937.52% in Q4 2024 and bottomed at 25084.21% in Q3 2024.